Effects of 10 Hz repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in the vegetative state

XIN GE1,3*, YUE ZHANG1*, TIAN XIN2 and XUE LUAN1

1Department of Neurosurgery and Coma Recovery, Central Hospital of Jinzhou, Jinzhou, Liaoning 121001; 2Medical Oncology Department of Thoracic Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China

Received August 29, 2019; Accepted July 7, 2020

DOI: 10.3892/etm.2021.9626

Abstract. The aim of the present study was to investigate the effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex (DLPFC) during vegetative state (VS). Between May 2017 and November 2018, 95 patients were treated in the Coma Recovery Department of the Central Hospital of Jinzhou. According to the inclusion and exclusion criteria, a total of 32 patients in VS caused by brain injury were enrolled. The patients were assigned into the rTMS and control groups in a non-randomized manner. All patients received JFK Coma Recovery Scale-Revised (CRS-R) scores and underwent motor evoked potential (MEP) latency and central motor conduction time (CMCT) measurement before the first treatment and after 20 days of treatment, which was the end of the study. Following 20 days of treatment, a significant increase was observed in the CRS-R scores of patients in the rTMS group compared with those obtained at pretreatment (P<0.001). An increase in the CRS-R scores of the control group was also observed compared with the pretreatment scores (P=0.035). The change in CRS-R scores (P<0.001) and improved conscious state rate (P=0.0016) were significantly different between the two groups. A significant decrease in MEP (P<0.001) and CMCT (P<0.001) was observed in the rTMS group compared with measurements obtained at pretreatment, whereas no significant decrease was observed in the control group (P=0.693; P=0.070). The changes in MEP (P<0.001) and CMCT (P<0.001) between the two groups were statistically significant. In conclusion, 10 Hz rTMS of the right DLPFC in early disorders of consciousness is feasible and efficient. rTMS treatment could improve patient state of awareness and accelerate patient recovery in VS.

Introduction

Coma induced by severe brain injury is a self-limiting state that typically resolves within 2 weeks (1). Severe and diffuse lesions of the cortex or underlying white matter, bilateral thalamic damage and brainstem injury account for the primary reasons of comas (1). After two weeks, comas are classified into disorders of consciousness (DOC), which can be divided into 2 subgroups: Vegetative state (VS) and minimally conscious state (MCS) (1). VS is a condition of a wakeful unconscious state. In VS, patients can spontaneously open their eyes, but without repetitive behavioral responses to verbal comprehension, verbal or gestural communication, and purposeful situations of visual, auditory, tactile and harmful stimuli (1,2). MCS is a condition of severely altered consciousness characterized by functional communication or functional use of objects (1,2). Patients with MCS showed a range of behavioral signs of inconsistent awareness and reliable communication (1,2). The use of multiple treatments for DOC recovery in different stages is necessary, including invasive and non-invasive treatments. Invasive methods, including deep brain and spinal cord stimulation, have ethical and procedural limitations (3,4) and are not suitable for early DOC. A report of non-invasive measures using electrical and magnetic stimulation of the brain, spinal cord and roots was endorsed by the first International Federation of Clinical Neuroelectrophysiology (IFCN) 30 years ago. Among developed neurostimulation techniques, non-invasive measures, including transcranial magnetic stimulation and transcranial direct current stimulation, may be promising for early DOC therapeutic intervention (5). However, there are still no sufficient evidence-based methods to treat DOC to date. During the past decade, several studies and clinical trials have demonstrated potential therapeutic applications of non-invasive brain stimulation, particularly for transcranial magnetic stimulation (TMS), which is non-invasive, safe, painless and effective in treating DOC (6-8).

A magnetic stimulating coil placed on the human scalp can generate a strong magnetic field by a rapid pulse current, which can penetrate the skull, causing secondary induction current at adjacent nerve tissues (9). The current acts on the cell membrane...
of cerebral cortical neurons, generating excitatory or inhibitory postsynaptic potentials to stimulate neurons that lead to altered cortical function (10,11). TMS can be applied one stimulus at a time (single-pulse TMS), in pairs of stimuli separated by a variable interval (paired-pulse TMS) or in trains repetitive TMS (rTMS) (3,11). rTMS focuses on a particular cortical site to improve neurophysiological functions and has been proven to have a neuromodulatory effect (3,7,11). Furthermore, its repetitive effect has been proven to be more effective than single-pulse and paired-pulse TMS in the treatment of DOC (12-16). rTMS is currently used for the treatment of several diseases such as depression, psychiatric illness, epilepsy, Parkinson's disease and cognitive dysfunction, and achieves satisfactory curative effects (16-20).

However, studies using rTMS to treat DOC have shown conflicting results. Louise-Bender Pape et al (6) reported a trend toward significant neurobehavioral gains by rTMS to stimulate the right dorsolateral prefrontal cortex (DLPFC) in a traumatic patient with VS/unresponsive wakefulness syndrome. Xie and Zhang (8) reported that rTMS treatment could improve consciousness disturbance in 10 patients with stroke as detected by quantitative electroencephalography spectral power analysis. Naro et al (21) found that a single session of 10 Hz rTMS over the right DLPFC may improve consciousness and partially restore the connectivity within several cortical areas, but no clinical effects were observed between the test and control groups. Liu et al (22) reported no behavioral improvement following one session of primary motor cortex (M1) 20 Hz rTMS for 10 min in 10 patients with DOC. However, hemodynamic functions were improved in the MCS group but not in the unresponsive wakefulness syndrome group. Bai et al (23) reported that an increased Coma Recovery Scale-Revised (CRS-R) score was observed in a female with intracranial hemorrhage for 9 months prior to receiving rTMS 30 times. No effect of rTMS on the DOC was reported in another study. Cincotta et al (24) reported a double-blinded randomized controlled trial comprising 74 patients with DOC. No behavioral improvements were found following five repeated sessions at 20 Hz applied over the M1 for 10 min in 11 patients with unresponsive wakefulness syndrome. For the diagnosis of a consciousness disorder, the target of rTMS stimulation may impact the efficacy of rTMS on DOC. The present study hypothesized that high-frequency rTMS stimulation on patients in VS could improve the consciousness state (CS) and CRS-R scores. The aim of the present study was to investigate the efficacy of rTMS on VS patients who received 10 Hz rTMS on the right DLPFC.

Materials and methods

Patients. In the present retrospective cohort study, all patients were recruited from the Departments of Neurosurgery and Coma Recovery (Central Hospital of Jinzhou, Jinzhou, China) and between May 2017 to November 2018. The Coma Recovery Department of Jinzhou Central Hospital is the first standard coma recovery and rehabilitation ward in northeast China. The inclusion criteria were as follows: i) Accepted coma treatments 2 weeks after admission; ii) aged 18-75 years; iii) vital signs were stable; iv) their CRS-R score was assessed by international criteria and they fulfilled the diagnostic criteria of VS (1); v) had no seizures or brain edema; vi) received no sedatives and anti-epilepsy drugs within the last 7 days; vii) informed consent was signed by patients of their legally authorized representative to participate in the present study. The exclusion criteria were as follows: i) No motor evoked potentials (MEP) were elicited; ii) severe dysfunction of heart, liver or kidney; iii) extreme complications, such as pneumonia and deep venous thrombosis; iv) seizures or skull scalp injury during treatment; v) craniootomy or metallic implantation on the right side of the head; vi) previous neurological or psychiatric disorders; vii) no 20 consecutive rTMS treatments in the rTMS group. There were two groups in the present study. The patients whose legally authorized representatives accepted rTMS treatment were allocated into the rTMS group and those who refused rTMS treatment were allocated into the control group. Finally, patient data was collected from 15 patients from the rTMS group and 17 patients from the control group. All patients received similar routine medication and rehabilitation course in our coma recovery ward.

Study design and stimulation protocol. The effect of rTMS is dependent on its frequency. Low-frequency rTMS (<1 Hz) can reduce neuronal excitability, local metabolism levels and cerebral blood flow, and inhibit cortical activity (13,25), whereas high-frequency rTMS (5-20 Hz) exerts the opposite effects. In addition, rTMS can affect the transmission of monoamine neurotransmitters and genetic expression of neuronal excitability in the brain (11,26). The patients in the rTMS group received active 10 Hz rTMS on the right DLPFC once per day over 20 consecutive days. TMS pulses were delivered using a Yiruide CCY-IA stimulator and a circular coil (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.), which can produce a pulse stimulation frequency of 0.01-100 Hz and a 2.0-T maximum magnetic field strength. The circular coil had a diameter of 10 cm, where stimulation is most effective under the coil. The minimal stimulation is in the center of the ring (15). The consciousness is dependent on the function of the cerebral cortex, which affects high-level central neural system function and bilateral hemisphere functional cortices that compete and suppress together, and the ascending reticular activating system that affects regular awakening (27,28). The key point for rTMS is the site of stimulation, which has been discussed in several studies. The DLPFC (6-8) and M1 (24,29,30) are the most common stimulation sites of choice. Several studies have chosen the left (7) or right (8) DLPFC as the site of stimulation, with positive outcomes. The right DLPFC is closely linked to the brain network structure, with the ascending reticular activating system connecting to the DLPFC and even the entire cortex, via the thalamic relay and raphe nuclei, which are the most important for DOC recovery (6). The maintenance of sustained arousal and attention are also cardinal functions of the right DLPFC (6).

Based on these reasons, the right DLPFC was selected as the stimulation site in the present study. The stimulation target is the most important parameter for rTMS treatment (27,30). The right hemisphere motor cortex was determined by MEP and the 5+1 cm prefrontal cortex in front of the right M1 was chosen as the right DLPFC (Fig. 1A) (31). The coil was placed tangentially toward the scalp over the right DLPFC for stimulation. Stimulation intensity is the second most important parameter for each patient and was determined based on the resting motor threshold (RMT). The stimulation intensity of RMT is also undefined. Xia et al (7) administered 90% RMT to patients.
with chronic DOC. Xie and Zhang (8) used 100% RMT to treat patients with DOC with stroke. However, high levels of intensity and frequency could trigger seizures. Cavinato et al. (32) reported that 20 Hz rTMS treatment could trigger frequent seizures. Most rTMS studies used 10 Hz and 100% RMT and had a lower risk of epilepsy (5,6,8). Based on the above consideration, 10 Hz and 100% RMT were chosen as the treatment parameters in the present study. According to the IFCN Committee recommendations (15), RMT was defined as the lowest TMS intensity to evoke at least 5/10 electromyogram with an amplitude of >50 µV peak-to-peak in the relaxed first dorsal interosseous muscle of the right hand (7,15). During RMT measurement, earplugs were inserted into the ears of patients, which continuously played a masking noise to prevent the interference of auditory potentials with TMS discharge. When the total number of pulses per treatment was >1,000 and the stimulation intensity was ≥100% RMT, the cure rate of patients was significantly increased. A single treatment of 1,000-2,000 pulses is safe and effective according to TMS guidelines (15). A single daily session of stimulation consisted of 1,575 pulses (10 Hz trains for 1.5 sec; repeated 105 times with an inter-train interval of 10 sec; total session, 20 min and 8 sec) at an intensity of 100% RMT (Fig. 1B) was applied in the present study. Meanwhile, patient routine medication and rehabilitation courses continued as usual during rTMS treatment.

**Outcome evaluation.** All patients received CRS-R scores and MEP latency and central motor conduction time (CMCT) measurements prior to the first treatment and after 20 days of treatment, which was the end of the study.

**Statistical analysis.** All statistical analysis was performed using GraphPad Prism 7.0 (GraphPad Software, Inc.). The Mann-Whitney U test, Wilcoxon matched pairs signed rank test, paired t-test, unpaired t-test and Fisher's exact probability tests were used for comparison between groups, as appropriate. Normally distributed data are expressed as the mean ± SD. Skewed distributed data are expressed as the median with interquartile range. P<0.05 was considered to indicate a statistically significant difference.
Results

Patient data in rTMS and control groups. All patients remained in a stable clinical state during routine medication and rehabilitation course. There were no focal lesions in the right DLPFC in all patients, as evidenced by their brain scans. Detailed clinical characteristics of participants are shown in Tables I and II. The mean age of the patients was 60.5±1.8 (range, 49‑70) years in the rTMS group and 59.7±2.1 (range, 39‑72) years in the control group (P>0.05). There were eight males and seven females in the rTMS group, including seven with ICH and eight with TBI and 10 males and seven females in the control group, including nine with ICH and eight with TBI. The admission time was 4.6±0.8 h in the rTMS group and 4.4±0.7 h in the control group (P>0.05). The mean CRS‑R score was 3.7±0.8 (3‑5) in the rTMS group and 3.8±0.8 (3‑5) in the control group (P>0.05). The mean MEP prior to treatment was 29.87±0.96 msec in the rTMS group and 30.02±0.98 msec in the control group (P>0.05). The mean CMCT before treatment was 11.04±0.24 msec in the rTMS group and 11.14±0.23 msec in the control group (P>0.05). Baseline data, including age, sex, etiology, admission age, admission GCS score, CRS‑R score, MEP and CMCT prior to treatment were not significantly different between the rTMS and control groups (Fig. 2).

Effects of the 10 Hz rTMS treatment protocol as determined by CRS‑R scores on day 20. A total of 15 patients in the rTMS group and 17 patients in the control group completed the treatment (Tables I and II), with no specific side effects recorded. There were no statistical differences between the two groups prior to treatment (Fig. 2). A significant increase in the CRS‑R scores (Fig. 3A; P<0.001) in the rTMS group was observed 20 days later compared with those at pretreatment. An increase in the CRS‑R scores (Fig. 3B; P=0.035) in the control group was also observed compared with those at pretreatment. The CRS‑R scores were increased in all patients in the rTMS group. A total of seven patients showed improved CRS‑R scores by >4 points in the rTMS group. Only two patients in the control group improved their CRS‑R scores by 3 points; however, no significant increase was observed in most patients. The median CRS‑R score change in the rTMS group improved by 3 points, whereas the control group improved by 1 point (Fig. 3C; P<0.001). Significant differences were observed in the improvement of the CS rate. In the rTMS group, 13 VS patients (86.7%) turned MCS‑, with only five patients (29.4%) in the control group (P=0.0016). In the rTMS group, the changes in CRS‑R scores of seven patients were ≥4 points at day 20 (Table III).

Effects of the 10 Hz rTMS treatment protocol as determined by MEP latency and CMCT measurements. The two groups of patients were examined using magnetic stimulation evoked potentials, the main indicators of which were MEP and CMCT. There were no statistical differences between the two groups prior to treatment (Fig. 2K; P=0.662; Fig. 2L; P=0.758). A significant decrease in the MEP and CMCT in the rTMS group were observed 20 days later compared with those at pretreatment (Fig. 3D; P<0.001; Fig. 3G; P<0.001), with no significant decrease in the control group (Fig. 3E; P=0.693; Fig. 3H; P=0.070). The changes in MEP and CMCT between the two groups were statistically significant (Fig. 3F; P<0.00; Fig. 3I; P<0.01).
Table I. Clinical data of the repetitive transcranial magnetic stimulation group.

| Patient | Age (years) | Sex | Etiology | Admission time, h | Admission GCS | CRS-R Day 1 | CRS-R Day 20 | MEP latency, msec Day 1 | MEP latency, msec Day 20 | CMCT, msec Day 1 | CMCT, msec Day 20 | CS |
|---------|-------------|-----|----------|------------------|---------------|-------------|-------------|------------------------|------------------------|----------------|----------------|-----|
| 1       | 65          | M   | ICH      | 4                | 4             | 3           | 5           | 31.04                  | 27.96                  | 12.45          | 12.03          | VS  |
| 2       | 55          | M   | TBI      | 3                | 5             | 4           | 8           | 29.81                  | 29.44                  | 11.09          | 10.21          | MCS-|
| 3       | 58          | F   | ICH      | 4                | 4             | 3           | 6           | 30.83                  | 27.15                  | 11.97          | 11.12          | MCS-|
| 4       | 62          | F   | TBI      | 2                | 5             | 4           | 7           | 29.13                  | 28.13                  | 10.54          | 9.86           | MCS-|
| 5       | 49          | M   | TBI      | 3                | 4             | 3           | 7           | 30.56                  | 29.84                  | 11.23          | 10.14          | MCS-|
| 6       | 52          | M   | TBI      | 2                | 4             | 3           | 6           | 31.27                  | 27.45                  | 12.37          | 11.84          | MCS-|
| 7       | 68          | F   | TBI      | 4                | 4             | 4           | 6           | 28.97                  | 29.21                  | 10.21          | 9.75           | MCS-|
| 8       | 50          | F   | ICH      | 4                | 4             | 3           | 7           | 30.07                  | 27.46                  | 11.08          | 10.26          | MCS-|
| 9       | 70          | M   | ICH      | 5                | 6             | 5           | 8           | 28.75                  | 30.01                  | 10.11          | 9.84           | MCS-|
| 10      | 65          | F   | TBI      | 3                | 4             | 3           | 5           | 31.66                  | 27.48                  | 12.58          | 11.46          | VS  |
| 11      | 57          | M   | ICH      | 6                | 6             | 5           | 9           | 28.97                  | 28.04                  | 9.75           | 9.43           | MCS-|
| 12      | 60          | F   | TBI      | 3                | 4             | 4           | 8           | 29.11                  | 28.96                  | 10.87          | 10.22          | MCS-|
| 13      | 63          | M   | ICH      | 5                | 5             | 4           | 7           | 29.35                  | 27.26                  | 10.34          | 9.94           | MCS-|
| 14      | 65          | F   | ICH      | 4                | 5             | 4           | 9           | 29.45                  | 27.88                  | 10.89          | 9.75           | MCS-|
| 15      | 69          | M   | TBI      | 3                | 5             | 4           | 8           | 29.14                  | 27.88                  | 10.11          | 10.03          | MCS-|

ICH, intracerebral hemorrhage; TBI, traumatic brain injury; GCS, Glasgow Coma Scale; CRS-R, JFK Coma Recovery Scale-Revised; MEP, motor evoked potentials; CMCT, central motor conduction time; CS, consciousness state; M, male; F, female; VS, vegetative state; MCS, minimally conscious state; -, negative.
Table II. Clinical data of the control group.

| Patient | Age (years) | Sex | Etiology | Admission time, h | Admission GCS | CRS-R Day 1 | CRS-R Day 20 | MEP latency, msec Day 1 | MEP latency, msec Day 20 | CMCT, msec Day 1 | CMCT, msec Day 20 | CS Day 20 |
|---------|-------------|-----|----------|------------------|--------------|------------|------------|----------------------|----------------------|----------------|----------------|---------|
| 1       | 68          | F   | ICH      | 4                | 4            | 3          | 3          | 31.84                | 31.55                | 12.67          | 12.58          | VS      |
| 2       | 65          | M   | ICH      | 5                | 4            | 3          | 4          | 30.95                | 31.01                | 12.14          | 11.99          | VS      |
| 3       | 52          | M   | TBI      | 3                | 5            | 4          | 5          | 30.13                | 30.05                | 11.75          | 11.37          | VS      |
| 4       | 63          | F   | ICH      | 5                | 4            | 4          | 5          | 29.45                | 29.34                | 10.98          | 10.56          | VS      |
| 5       | 59          | F   | TBI      | 3                | 5            | 4          | 6          | 29.63                | 29.55                | 11.04          | 10.88          | MCS-    |
| 6       | 39          | M   | ICH      | 3                | 6            | 4          | 7          | 29.97                | 28.88                | 11.34          | 10.01          | MCS-    |
| 7       | 56          | F   | TBI      | 2                | 5            | 5          | 7          | 28.74                | 28.05                | 10.13          | 9.59           | VS      |
| 8       | 57          | M   | TBI      | 3                | 4            | 4          | 6          | 29.03                | 28.93                | 10.21          | 10.09          | MCS-    |
| 9       | 69          | M   | ICH      | 5                | 4            | 3          | 4          | 31.37                | 32.01                | 12.45          | 12.56          | VS      |
| 10      | 71          | F   | ICH      | 4                | 3            | 3          | 3          | 30.87                | 32.54                | 11.97          | 12.01          | VS      |
| 11      | 62          | M   | TBI      | 4                | 4            | 3          | 4          | 31.41                | 30.61                | 12.47          | 12.06          | VS      |
| 12      | 72          | M   | ICH      | 6                | 5            | 5          | 5          | 28.87                | 28.64                | 10.11          | 10.13          | VS      |
| 13      | 49          | F   | TBI      | 4                | 4            | 3          | 6          | 30.21                | 29.15                | 10.87          | 10.22          | MCS-    |
| 14      | 60          | M   | TBI      | 4                | 4            | 3          | 4          | 29.95                | 29.74                | 10.54          | 10.45          | VS      |
| 15      | 54          | M   | ICH      | 4                | 5            | 4          | 5          | 29.87                | 28.93                | 10.89          | 10.57          | VS      |
| 16      | 56          | F   | ICH      | 5                | 4            | 5          | 3          | 28.98                | 29.88                | 9.89           | 10.51          | VS      |
| 17      | 62          | M   | TBI      | 3                | 4            | 5          | 3          | 29.01                | 30.13                | 9.97           | 11.06          | VS      |

ICH, intracerebral hemorrhage; TBI, traumatic brain injury; GCS, Glasgow Coma Scale; CRS-R, JFK Coma Recovery Scale-Revised; MEP, motor evoked potentials; CMCT, central motor conduction time; CS, consciousness state; M, male; F, female; VS, vegetative state; MCS, minimally conscious state; -, negative.
Table III. Changes of ≥4 points in CRS-R scores at day 20 in the rTMS group.

| Patient no. | Day | Auditory | Visual | Motor | Oro-motor | Comm | Arousal | Total | CS        |
|------------|-----|----------|--------|-------|-----------|------|---------|-------|-----------|
|            |     |          |        |       |           |      |         |       |           |
| 2          | 1   | 1        | 1      | 2     | 0         | 0    | 0       | 4     | VS        |
| 20         |     |          |        |       |           |      |         |       |           |
| 5          | 1   | 1        | 1      | 1     | 0         | 0    | 0       | 3     | VS        |
| 20         |     |          |        |       |           |      |         |       |           |
| 8          | 1   | 1        | 1      | 1     | 0         | 0    | 0       | 3     | VS        |
| 20         |     |          |        |       |           |      |         |       |           |
| 11         | 1   | 1        | 1      | 2     | 0         | 0    | 1       | 5     | VS        |
| 20         |     |          |        |       |           |      |         |       |           |
| 12         | 1   | 1        | 1      | 2     | 0         | 0    | 0       | 4     | VS        |
| 20         |     |          |        |       |           |      |         |       |           |
| 14         | 1   | 1        | 1      | 2     | 0         | 0    | 0       | 4     | VS        |
| 20         |     |          |        |       |           |      |         |       |           |
| 15         | 1   | 1        | 1      | 2     | 0         | 0    | 0       | 4     | VS        |
| 20         |     |          |        |       |           |      |         |       |           |

Comm, communication; CS, consciousness state; CRS-R, JFK Coma Recovery Scale-Revised; VS, vegetative state; MCS, minimally conscious state; -, negative.

Figure 3. Data following 20 days of treatment for the rTMS and control groups. (A) A significant increase in the CRS-R scores compared with pretreatment in the (A) rTMS and (B) control groups. (C) The changes in CRS-R scores between the two groups were statistically significant. (D) A significant decrease in the MEP of the rTMS group compared with pretreatment. (E) No significant decrease in the MEP of the control group compared with pretreatment. (F) The changes in MEP between the two groups were statistically significant. (G) A significant decrease in the CMCT of the rTMS group compared with pretreatment. (H) No significant decrease in the CMCT of the control group compared with pretreatment. (I) The changes in CMCT between the two groups were statistically significant. CRS-R, JFK Coma Recovery Scale-Revised; MEP, motor evoked potentials; CMCT, central motor conduction time; rTMS, repetitive transcranial magnetic stimulation; pre, prior to treatment; post, after treatment; ms, milliseconds.
Discussion

The aim of the present study was to investigate the effects of 10 Hz rTMS at the right DLPFC in patients with VS. The present results demonstrated that 10 Hz rTMS at the right DLPFC could improve CS from VS to MCS-, increase the CRS-R score and decrease MEP and CMCT. CS was the main factor that could affect the outcome evaluation, since VS and MCS were fundamentally different in DOC (1,2,33). Functional neuroimaging has previously verified that MCS+ patients preserve greater metabolic activity and resting state functional connectivity in the language network (33,34). It is important to distinguish VS form MCS, as misdiagnosis can affect the outcome of a study (35). It was confirmed that functional outcome was significantly more favorable for patients in MCS relative to those in VS, especially for traumatic brain injury (36,37). All participants were in VS, as determined by their CRS-R (measured three times), in our departments. The CRS-R score was the highest score assessed by three trained physicians. Patients who had recently used antiepileptics and sedatives were excluded from the current study, as these drugs can have a significant impact on the accurate scoring of patients. After 20 days of treatment, an increase in the CRS-R scores in the control group was also observed compared with the pretreatment scores that may be caused by an insufficient number of cases and insufficient self-recovery following brain injury in certain patients. However, the change in CRS-R scores was significantly different between the two groups. Patient no. 14 from the rTMS group was used as a sample. Prior to treatment, she had an occasional response to sound and a startle response when the physician’s finger approached her eyeballs. Flexing was observed when her upper limbs were stimulated; however, she could not open her eyes. Her CRS-R scores for auditory, motor and oro-motor function had increased by 1 point 20 days after treatment. Her arousal score increased by 2 points. She could open her eyes spontaneously, locate sound and respond to pain in her upper limbs. She was also occasionally able to put the surface of her tongue between her lips. Her behavior had improved and the increased CRS-R score was 5. Behavioral improvements were also observed in 13 VS patients from in the rTMS group. Auditory and motor functions and arousal are major aspects of behavioral improvement (8). The findings of the present study were similar to those in the reports of Louise-Bender Pape et al (6) and Xie and Zhang (8). The choice of DLPFC as the stimulating target might be the reason for the significant increase in arousal. It was shown that 10 Hz rTMS at the right DLPFC in early VS is feasible and efficient. MEP latency and amplitude, as well as CMCT, were used as evaluation indicators by Barker et al (9) in 1985. Cakar et al (38) reported that MEP latency and amplitude, as well as CMCT, exhibited a correlation with clinical parameters and daily life functionality in 22 chronic post-stroke patients. Shorter MEP latency and faster CMCT were positively correlated with improved clinical measurements. The data of the present study, which demonstrated that rTMS treatment could increase the conduction velocity of the central nervous system. Additionally, treatment enhanced the excitability of central neurons and the function of the cerebral cortex to activate the ascending reticular activating system, which affects regular awakening, were similar to the results obtained by Cakar et al (38). The present study focused on recovery outcomes of early VS patients, which is rarely reported in current studies. Early functional recovery could enhance the confidence of doctors and family members to continue treatment, avoiding abandonment of treatment for some VS patients who might recover. The present study was not, however, without its limitations. The present study had a relatively small sample size and was a monocentric retrospective cohort study, lacking randomization and a sham group. It lacked measures of the patient long term outcome as many factors affected long term prognosis after treatment including family, economy and follow-up treatment levels. The data for 3- and 6-month follow-ups were incomplete for various reasons. A multicenter, randomized and sham treatment study should be conducted in the future.

In conclusion, 10 Hz rTMS at the right DLPFC in early DOC is feasible and efficient. rTMS treatment could significantly improve patient state of awareness and accelerate their recovery in early VS.

Acknowledgements

Not applicable.

Funding

The current study was supported by the Scientific Technology Research Projects of Jinzhou (grant no. 16B1G37).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XG designed the study. XG, YZ and XL drafted the manuscript. XG, YZ and XL collected and statistically analyzed data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of the Central Hospital of Jinzhou (Jinzhou, China). Written informed consent was obtained from each patient’s legally authorized representative.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Giacino JT, Fins JJ, Laureys S and Schiff ND: Disorders of consciousness after acquired brain injury: The state of the science. Nat Rev Neurol 10: 99-114. 2014.
2. Wu DY, Cai G, Yuan Y, Liu L, Li GQ, Song WQ and Wang MB: Application of nonlinear dynamics analysis in assessing unconsciousness: A preliminary study. Clin Neurophysiol 122: 490‑498, 2011.
3. Guerra A, Costantini EM, Maatta S, Ponzo D and FerrerI F: Disorders of consciousness and electrophysiological treatment strategies: A review of the literature and new perspectives. Curr Pharm Des 20: 4248‑4267, 2014.
4. Shin SS, Dixon CE, Okonkwo DO and Richardson RM: Neuronavigation for traumatic brain injury. J Neurosurg 121: 1219‑1231, 2014.
5. Rossini PM, Barker AT, Berardelli A, Caramia MD, Caruso G, Cracco RQ, Dimitrijević MR, Hallett M, Katayama Y, Lücking CH, et al: Noninvasive electrical and magnetic stimulation of the brain: Basic principles and protocols for routine clinical application. Report of an IFNCN committee. Electroencephalogr Clin Neurophysiol 91: 79‑92, 1994.
6. Louise‑Bender Pepe T, Rosenow J, Lewis G, Ahmed G, Walker M, Gueron A, Roth H and Patil V: Repetitive transcranial magnetic stimulation‑associated neuropsychological gains during coma recovery. Brain Stimul 2: 22‑35, 2009.
7. Xia X, Bai Y, Zhou Y, Yang Y, Xu R, Gao X, Li X and He J: Effects of 10 Hz repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in disorders of consciousness. Front Hum Neurosci 183, 2017.
8. Xie Y and Zhong F: Repetitive transcranial Magnetic Stimulation improves Consciousness disturbance in stroke patients: A quantitative electroencephalography spectral power analysis. Neural Regen Res 7: 2465‑2472, 2012.
9. Barker AT, Lalinos R and Freeston IL: Non‑invasive magnetic stimulation of the motor cortex. Lancer 1: 1106‑1107, 1987.
10. Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Mazzone P, Insola A, Tonali PA and Rothwell JC: The physiological basis of transcranial motor cortex stimulation in conscious humans. Clin Neurophysiol 115: 255‑266, 2004.
11. Chervyakov AV, Chernyavsky‑AY, Smitsyn DO and Piradov MA: Possible mechanisms underlying the therapeutic effects of transcranial magnetic stimulation. Front Hum Neurosci 9: 303, 2015.
12. Maeda F, Keenan JP, Tormos JM, Topin A and Pascual‑Leone A: Motor‑evoked potentials to hand dexterity, motor function, and specificity of the coma recovery Scale‑revised total score in 2 to 5 years after traumatic brain injury. Arch Phys Med Rehabil 86: 365‑371, 2015.
13. Xie Y, Luecking C, Klass N, Lauer K, Unterberg A, Wolf K, Marsden CD, Rothwell JC, Isermann H, et al: Functional neuroanatomy underlying the clinical subcategorization of consciousness by using TMS‑EEG. Front Neurosci 10: 473, 2016.
14. Rossini PM, Caramia MD, Caruso G, Cracco RQ, Dimitrijević MR, Hallett M, Katayama Y, Lücking CH, et al: Noninvasive electrical and magnetic stimulation of the brain: Basic principles and protocols for routine clinical application. Report of an IFNCN committee. Electroencephalogr Clin Neurophysiol 91: 79‑92, 1994.
15. Rossini PM, Barker AT, Berardelli A, Caramia MD, Caruso G, Cracco RQ, Dimitrijević MR, Hallett M, Katayama Y, Lücking CH, et al: Noninvasive electrical and magnetic stimulation of the brain: Basic principles and protocols for routine clinical application. Report of an IFNCN committee. Electroencephalogr Clin Neurophysiol 91: 79‑92, 1994.
16. Louise‑Bender Pepe T, Rosenow J, Lewis G, Ahmed G, Walker M, Gueron A, Roth H and Patil V: Repetitive transcranial magnetic stimulation‑associated neuropsychological gains during coma recovery. Brain Stimul 2: 22‑35, 2009.